JNJ

190.6

-0.77%↓

ABT

126.77

+0.33%↑

MDT

93.77

-0.45%↓

VEEV

293.21

+0.68%↑

A

148.21

+0.39%↑

JNJ

190.6

-0.77%↓

ABT

126.77

+0.33%↑

MDT

93.77

-0.45%↓

VEEV

293.21

+0.68%↑

A

148.21

+0.39%↑

JNJ

190.6

-0.77%↓

ABT

126.77

+0.33%↑

MDT

93.77

-0.45%↓

VEEV

293.21

+0.68%↑

A

148.21

+0.39%↑

JNJ

190.6

-0.77%↓

ABT

126.77

+0.33%↑

MDT

93.77

-0.45%↓

VEEV

293.21

+0.68%↑

A

148.21

+0.39%↑

JNJ

190.6

-0.77%↓

ABT

126.77

+0.33%↑

MDT

93.77

-0.45%↓

VEEV

293.21

+0.68%↑

A

148.21

+0.39%↑

Search

Danaher Corp

Suletud

SektorTervishoid

223.58 0.49

Ülevaade

Aktsiahinna muutus

24h

Praegune

Min

223.09

Max

223.98

Põhinäitajad

By Trading Economics

Sissetulek

-399M

555M

Müük

195M

5.9B

P/E

Sektori keskmine

44.433

37.461

Aktsiakasum

0.77

Dividenditootlus

0.56

Kasumimarginaal

9.35

Töötajad

61,000

EBITDA

-455M

1.3B

Soovitused

By TipRanks

Soovitused

Tugev "osta" hinnang

12 kuu keskmine prognoos

+9.17% upside

Dividendid

By Dow Jones

Dividenditootlus

Sektori keskmine

0.56%

2.33%

Järgmine dividendimakse kuupäev

31. okt 2025

Turustatistika

By TradingEconomics

Turukapital

15B

150B

Eelmine avamishind

223.09

Eelmine sulgemishind

223.58

Uudiste sentiment

By Acuity

39%

61%

111 / 371 Pingereas Healthcare

Tehniline skoor

By Trading Central

Kindlus

Bullish Evidence

Danaher Corp Graafik

Mineviku tootlus ei ole usaldusväärne näitaja tulevaste tulemuste kohta.

Seotud uudised

21. okt 2025, 17:41 UTC

Tulu

Danaher 3Q Earnings Rise; Pharma R&D Spend Expected to Rebound -- Update

21. okt 2025, 10:28 UTC

Tulu

Danaher 3Q Sales and Profit Rise on Bioprocessing Momentum

22. juuli 2025, 11:32 UTC

Tulu

Danaher Posts Lower 2Q Profit, Names Next CFO -- Update

22. juuli 2025, 10:42 UTC

Tulu

Danaher Posts Higher 2Q Sales, Lower Profit

22. apr 2025, 10:34 UTC

Tulu

Danaher 1Q Results Decline But Top Estimates

21. okt 2025, 10:02 UTC

Tulu

Danaher 3Q Adjusted Core Revenue Rose 3% >DHR

21. okt 2025, 10:01 UTC

Tulu

Danaher Sees 2025 Adjusted Core Revenue Up Low-Single Digits >DHR

21. okt 2025, 10:01 UTC

Tulu

Danaher Backs 2025 View of Adj EPS $7.70-Adj EPS $7.80 >DHR

21. okt 2025, 10:00 UTC

Tulu

Danaher 3Q Operating Cash Flow $1.7B, Free Cash Flow $1.4B >DHR

21. okt 2025, 10:00 UTC

Tulu

Danaher 3Q Net $908M >DHR

21. okt 2025, 10:00 UTC

Tulu

Danaher 3Q Sales $6.05B >DHR

21. okt 2025, 10:00 UTC

Tulu

Danaher 3Q Adj EPS $1.89 >DHR

21. okt 2025, 10:00 UTC

Tulu

Danaher 3Q EPS $1.27 >DHR

22. juuli 2025, 10:03 UTC

Tulu

Danaher Had Seen 2025 Adjusted EPS $7.60-$7.75 >DHR

22. juuli 2025, 10:03 UTC

Tulu

Danaher Raises 2025 View To Adj EPS $7.70-Adj EPS $7.80 >DHR

22. juuli 2025, 10:02 UTC

Tulu

Danaher Still Sees 2025 Core Revenue Up About 3% >DHR

22. juuli 2025, 10:01 UTC

Tulu

Danaher Sees 3Q Core Revenue Up Low-Single Digits >DHR

22. juuli 2025, 10:00 UTC

Tulu

Danaher 2Q Operating Cash Flow $1.3B, Free Cash Flow $1.1B >DHR

22. juuli 2025, 10:00 UTC

Tulu

Danaher 2Q Net $555M >DHR

22. juuli 2025, 10:00 UTC

Tulu

Danaher 2Q Sales $5.9B >DHR

22. juuli 2025, 10:00 UTC

Tulu

Danaher 2Q Adj EPS $1.80 >DHR

22. juuli 2025, 10:00 UTC

Tulu

Danaher 2Q EPS 77c >DHR

22. juuli 2025, 09:34 UTC

Kuumad aktsiad

Stocks to Watch Tuesday: Coca-Cola, GM, AstraZeneca, NXP -- WSJ

14. juuli 2025, 16:12 UTC

Market Talk
Omandamised, ülevõtmised, äriostud

Waters Closer to Thermo Fisher, Danaher With Becton Dickinson Unit -- Market Talk

22. apr 2025, 10:02 UTC

Tulu

Danaher Still Sees 2025 Adjusted Core Revenue Up About 3% >DHR

22. apr 2025, 10:02 UTC

Tulu

Danaher Sees 2025 Adj EPS $7.60-Adj EPS $7.75 >DHR

22. apr 2025, 10:02 UTC

Tulu

Danaher Sees 2Q Adjusted Core Revenue Up Low-Single Digits >DHR

22. apr 2025, 10:01 UTC

Tulu

Danaher: Macro Backdrop Has Become More Dynamic Since Start of Year >DHR

22. apr 2025, 10:01 UTC

Tulu

Danaher 1Q Adjusted Core Revenue Flat >DHR

22. apr 2025, 10:00 UTC

Tulu

Danaher 1Q Operating Cash Flow $1.3B, Adjusted Free Cash Flow $1.1B >DHR

Võrdlus sarnastega

Hinnamuutus

Danaher Corp Prognoos

Hinnasiht

By TipRanks

9.17% tõus

12 kuu keskmine prognoos

Keskmine 243.45 USD  9.17%

Kõrge 260 USD

Madal 220 USD

Põhineb 14 Wall Streeti analüütiku instrumendi Danaher Corp 12 kuu hinnasihil - viimase 3 kuu andmed.

Hinnangu Konsensus

By TipRanks

Tugev "osta" hinnang

14 ratings

11

Osta

3

Hoia

0

Müü

Tehniline skoor

By Trading Central

189.8851 / 196.5Toetus ja vastupanu

Lühikene perspektiiv

Bullish Evidence

Keskpikk perspektiiv

Weak Bullish Evidence

Pikk perspektiiv

Neutral Evidence

Sentiment

By Acuity

111 / 371 Pingereas Tervishoid

Uudiste sentiment

Languse märgid

Volatiilsus

Alla keskmise

Uudismaht (RCV)

Alla keskmise

Finantsandmed

Müügi- ja halduskulud

Tegevuskulud

Maksueelne kasum

Müük

Müügikulu

Brutokasum müügist

Intressikulud võla pealt

EBITDA

Ärikasum

$

Ettevõttest Danaher Corp

Danaher Corporation designs, manufactures, and markets professional, medical, industrial, and commercial products and services worldwide. The Biotechnology segments offers bioprocess technologies, consumables, and services that advance, accelerate, and integrate the development and manufacture of therapeutics; cell line and cell culture media development services; cell culture media, process liquids and buffers for manufacturing, chromatography resins, filtration technologies, aseptic fill finish; single-use hardware and consumables and services, such as the design and installation of full manufacturing suites; lab filtration, separation, and purification; lab-scale protein purification and analytical tools; reagents, membranes, and services; and healthcare filtration solutions. The Life Sciences segment provides mass spectrometers; flow cytometry, genomics, lab automation, centrifugation, liquid handling automation instruments, antibodies and reagents, and particle counting and characterization; microscopes; protein consumables; industrial filtration products; and genomic medicines, such as custom nucleic acid products, plasmid DNA, RNA, and proteins under the ABCAM, ALDEVRON, BECKMAN COULTER, IDT, LEICA MICROSYSTEMS, MOLECULAR DEVICES, PALL, PHENOMENEX and SCIEX brands. The Diagnostics segment offers chemistry, immunoassay, microbiology, and automation systems; and molecular, acute care, and pathology diagnostics products. This segment also provides clinical instruments, reagents, consumables, software, and services for hospitals, physicians' offices, reference laboratories, and other critical care settings. The company has a research collaboration with Stanford University's Department of Bioengineering for cancer drug development. The company was formerly known as Diversified Mortgage Investors, Inc. and changed its name to Danaher Corporation in 1984. Danaher Corporation was founded in 1969 and is based in Washington, the District of Columbia.
help-icon Live chat